

Curriculum Vitae

Name: Prof. Dr. Eberhard Hildt
 Address:
 Paul-Ehrlich-Institute; Department of Virology
 Paul-Ehrlich-Str. 51-59
 D-63225 Langen
 email: eberhard.hildt@pei.de
 phone : ++496103772140/41

Date and place of birth: December, 08, 1964, in Karlsruhe, Germany

Education:

1971-1975 Elementary school, Karlsruhe, Germany
 1975-1984 Max-Planck-Gymnasium, Karlsruhe
 Abitur: June, 1984,

Military service

07/1984-09/1985 Medical Corps II, Marburg, Germany

Undergraduate studies:

1985-1991 Undergraduate studies in 1989-1994 in Biochemistry at the University of Tübingen, Germany

1989 – 1990 Practical year at the Max-Planck-Institute for Biochemistry in Martinsried and at the Ludwig-Maximilians-University Munich, Germany

1991 Diploma thesis at the University of Tuebingen, Institute for Biochemistry, in the department of Prof. Dr. P. Bohley
Title: Posttranslational arginylation and ubiquitination of cytosolic propteins in dictyostelium discoideum

Graduate studies:

1992 – 1995 Ph.D. thesis at the Max-Planck-Institute for Biochemistry in Martinsried, Germany, in the laboratory of Prof. Dr. Dr. P.H. Hofschneider
Title: Functional and structural analysis of the Hepatitis B virus regulatory protein MHBs[†]

Professional experience

1996-1997 1996-1997: Postdoc at Max-Delbrück-Center for Molecular Medicine, Berlin-Buch and University Ulm: Topic: TNF α -dependent signal transduction/ modulation of apoptosis

1997-1999 Head of research group at the Institute for experimental therapy and tumor research, Technical University Munich, Topic: signal transduction, non-viral gene transfer

1999 visiting guest scientist Stanford University Medical Center Dr. Munz

1999-2004 Head of junior research group Molecular virology at the Robert Koch Institute; research interests: HBV and HCV associated carcinogenesis; signal transduction cascades involved in HBV and HCV replication; viral escape mechanisms; cell permeable peptides; gene transfer systems

2005 Head of independent research group Molecular virology of hepatitis viruses at the Department Internal Medicine II, University of Freiburg; research interests: HBV and HCV associated carcinogenesis; signal transduction cascades involved in HBV and HCV replication; viral escape mechanisms; TNF-dependent signal transduction; cell permeable peptides; gene and epitope transfer systems for vaccine development

2006-2007 Habilitation in Experimental Medicine "*Characterization of functional and structural prerequisites for HBV replication*"

2007-2011 Professor for Molecular Medical Virology, University of Kiel

2011 Head of the Virology Division at the Paul-Ehrlich- Institute in Langen

Management and administrative functions

2000-2002	Speaker junior research groups at the Robert Koch-Institute and Member of the research council of the Robert-Koch-Institute
2002	Co-founder of PepPer Biotech GmbH
2002-2004	Board member and acting CSO of the PepPer Biotech GmbH
2000-	Reviewer for Hepatology, Journal of Hepatology, Oncogene, Journal of General Virology, Lancet, WJG, Gut, Virology, Journal of Virology, Nature Medicine, Journal of Biological Chemistry, Nature
2002-	Member of the selection committee of the German National Academic Foundation
2005-	Editorial board member World Journal of Gastroenterology
2006-	Scientific board member Molecular Medicine foundation (Zurich)
2009-2011	Member of the MD-graduation committee of the Medical Faculty at the CAU Kiel
2011-	Member of the AOLG (Arbeitsgemeinschaft der oberen Landesgesundheitsbehörden)
2011-	Member of the working group developing the national pandemic plan
2011-	Member of thesis committees of the Medical Faculty and of the Department of Biological Sciences at the Johann-Wolfgang-Goethe-University Frankfurt
2012-	Member of the national expert committee influenza at RKI
2013-	Editorial board member World Journal of Hepatology
2016-	Editorial board member Bundesgesundheitsblatt

Honors and awards:

1986-1991	Fellowship of the German National Academic Foundation ("Studienstiftung des Deutschen Volkes"), Germany
-----------	---

1995	Otto-Hahn-medal of the Max-Planck-Gesellschaft, Germany
1998	Research award from the "Münchner Medizinische Wochenschrift"
1999	poster award german association for virology
2001	Invited speaker Gordon Research conference
2004	Invited speaker Bioethics symposium, University Linz
2008-11	Member "Excellence cluster inflammation at interfaces"
2011	Extraordinary professor in the medical faculty of the Johann-Wolfgang-Goethe Universität, Frankfurt

Patents:

- Use of thiol compounds for therapy of viral infections DE000004325547C2
- Polypeptide mediating cell permeability DE 19850718C1/EP000001127133A2
- Particles for Gene Therapy DE 199 04 800.2-41 EP000001165797A2
- Increasing of the resorption of substances via skin and mucous membranes PCT/EP2003/009788

10 selected publications

1. **Hildt, E.**, Oess, S. (1999). Identification of Grb2 as a novel binding partner of tumor necrosis factor (TNF) receptor I. J. Exp. Med. 189: 1707-1714.
2. **Hildt, E.**, Munz, B., Saher, G., Reifenberg, K., Hofschneider, P.H. (2002) The PreS2 activator MHBst of the Hepatitis b virus activates c-raf-1/ERK2-signaling in transgenic mice EMBO, J, 21, 525-535
3. Stoeckl, L., Funk, A., , Kopitzki, A., Oess, S., , Will, H., Sirma, H. and **Hildt, E.** (2006) Identification of a novel structural motif crucial for infectivity of hepatitis B viruses; PNAS,103,6730-6734
4. Himmelsbach K, Sauter D, Baumert T, Ludwig L, Blum H, and **Hildt E.** (2009) New aspects of an anti-tumor drug: sorafenib efficiently inhibits HCV replication. GUT, 58(12):1644-53

5. Ploen, D., Himmelsbach, K., Schuster, C, Biniossek, M., Sauter, D., Baumert, T.F., **Hildt, E.** (2013) TIP47 plays a crucial role in the life cycle of hepatitis C virus, *J Hepatol.*;58(6):1081-8.
6. Hofmann, J, Boehm, C, Himmelsbach, K, Ploen, D., Weiss, T. **Hildt, E.** (2013) Identification of a-taxilin as an essential factor for the life cycle of Hepatitis B *J Hepatol.* 59(5):934-41
7. Peiffer KH, Akhras S, Himmelsbach K, Hassemer M, Finkernagel M, Carra G, Nuebling M, Chudy M, Niekamp H, Glebe D, Sarrazin C, Zeuzem S, and **Hildt, E.** (2015), Intracellular accumulation of subviral particles and diminished Nrf2 activation in hepatitis B virus genotype G expressing *J Hepatol.* 62(4):791-85
8. Barthel SR, Medvedev R, Heinrich T, Büchner SM, Kettern N, **Hildt E.** (2016) Hepatitis B virus inhibits insulin receptor signaling and impairs liver regeneration via intracellular retention of the insulin receptor. *Cell Mol Life Sci.* 2016 Nov;73(21):4121-40, Elgner F, Ren H, Medvedev R, Ploen D, Himmelsbach K, Boller K, Hildt E. (2016) The Intracellular Cholesterol Transport Inhibitor U18666A Inhibits the Exosome-Dependent Release of Mature Hepatitis C Virus. *J Virol.* 90(24):11181-11196.
9. Akhras S, Toda M, Boller K, Himmelsbach K, Elgner F, Biehl M, Scheurer S, Gratz M, Vieths S, **Hildt E.** (2017) Cell-permeable capsids as universal antigen carrier for the induction of an antigen-specific CD8+ T-cell response. *Sci Rep.* 29;7(1):9630-9.
10. Medvedev, R., Ploen, D., Spengler, C., Elgner, F., Ren, H., Bunten, S, **Hildt, E.** (2017) HCV-induced oxidative stress by inhibition of Nrf2 triggers autophagy and favors release of viral particles. *Free Radicals Biology & Medicine*;110:300-315,